The Institute for Clinical and Economic Review (ICER) last week ruled...

...two highly anticipated (and potential blockbuster) drugs, Novartis' Mayzent and Janssen's Spravato, are not cost effective. The nonprofit industry watchdog said Spravato, which holds covered status for just 3% of all insured lives, should lower its list price by 25% to 52%. In Mayzent's case, ICER said payers should grant preferred formulary status to a generic variant of Novartis' Gilenya instead, once it hits the market. For the treatment of Multiple Sclerosis, Mayzent currently holds preferred status for 6% of covered lives, with step therapy and/or prior authorization.

SOURCE: MMIT Analytics, as of 6/24/19